AU2013202982C1 — Heterocyclic compounds and methods for their use
Assigned to Novartis AG · Expires 2017-01-05 · 9y expired
What this patent protects
The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT 2) recept or. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in f4 methods of treating or preventi…
USPTO Abstract
The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT 2) recept or. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in f4 methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammat ory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, dis orders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve re generation.
Drugs covered by this patent
- Xcopri (CENOBAMATE) · Sk Life
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.